Infectious Disease Therapeutics Market Likely To Reach A Valuation Of Around USD 86.2 Billion By 2025:Key Participant Janssen Pharmaceutical, Inc., F. Hoffmann-La Roche Ltd.

San Francisco, 31 December 2018,  Infectious Disease Therapeutics Market Analysis By Disease Type (HIV infection, Influenza, Malaria, Tuberculosis, Hepatitis, and HPV infection), By Region, And Segment Forecasts, 2018 – 2025.

The global top6 infectious disease therapeutics market is expected to reach USD 86.2 billion by 2025, according to a new report by Grand View Research, Inc. The market is primarily driven by increasing number of Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), TB, and hepatitis cases globally.

Government and private organizations are investing heavily in the healthcare sector to prevent, diagnose, and treat infectious diseases; rising investments for development of new drugs to treat infectious diseases, and increasing number of initiatives for creating awareness about these conditions are expected to boost the market during the forecast period. Furthermore, increasing number of patent expirations and entry of generic drugs in the market are expected to increase the demand for infectious disease therapeutics due to their low prices.

In addition, availability of reimbursement for diagnosis & treatment of these infections and free distribution of drugs by manufacturers in regions with high incidence of these diseases are factors further expected to propel the market growth. However, low penetration rate of anti-infective and availability of large number of counterfeit drugs are expected to restraint the market growth during the forecast period.

North American market held the largest share in 2016. Presence of large number of manufacturers, favorable reimbursement scenario, and increasing healthcare expenditure are major factors responsible for the largest share held by this region. However, Asia Pacific is likely to grow at the highest rate between 2017 and 2025. High prevalence of infectious diseases; improving economic conditions in Asian countries, rising government initiatives to increase the adoption of treatments for infectious diseases, and rising funding activities are factors that can be attributed for the highest growth rate of this region during the forecast period.

Access Full Research Report On Infectious Disease Therapeutics Market Analysis:www.grandviewresearch.com/industry-analysis/infectious-disease-therapeutics-market

Further Key Findings From the Report Suggest:

·         The HIV therapeutics segment held the largest revenue share in 2016 due to high number of HIV cases globally

·         North America dominated the global market owing to the strong reimbursement framework coupled with high adoption rate of treatments for infectious diseases

·         The HPV therapeutics segment is estimated to grow at the highest rate during the forecast period

·         Some of the key players areNovartis AG, Gilead, GlaxoSmithKline plc, Janssen Pharmaceutical, Inc., F. Hoffmann-La Roche Ltd., BioCryst Pharmaceuticals, Inc., and Boehringer Ingelheim GmbH

Browse More Reports Of This Category By Grand View Research At:  www.grandviewresearch.com/industry/medical-devices

Grand View Research has segmented the top 6 infectious disease therapeutics market on the basis of disease type and region:

Disease Type Outlook (Revenue, USD Million, 2014 - 2025)

·         HIV

o    Emtriva

o    Aptivus

o    Isentress

o    Lexiva/Telzir

o    Selzentry

o    Tivicay 

o    Atripla

o    Complera

o    Genvoya

o    Odefsey

o    Stribild

o    Truvada

o    Triumeq

o    Descovy

o    Vitekta

o    Others

·         Influenza

o    Relenza

o    Tamiflu 

o    Rapivab 

o    Others

·         TB

o    Sirturo

o    Others

·         Malaria

o    Coartem

o    Others

·         HPV

·         Hepatitis

Regional Outlook (Revenue, USD Million, 2014 - 2025)

·         North America

o    U.S.

o    Canada

·         Europe

o    Germany

o    UK

·         Asia Pacific

o    China

o    Japan

·         Latin America

o    Brazil

o    Mexico

·         Middle East & Africa

o    South Africa

Access Full Press Release of this Report:

www.grandviewresearch.com/press-release/global-infectious-disease-therapeutics-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com/

Cystic Fibrosis Therapeutics Market Expected To Trigger A Revenue Increase To USD 13.9 Billion By 2025:Key Participant AbbVie Inc., F. Hoffmann-La Roche Ltd.

San Francisco, 24 December 2018,  Cystic Fibrosis (CF) Therapeutics Market Analysis By Drug Class (Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, CFTR Modulators), By Route of Administration, By Region, And Segment Forecasts, 2018 - 2025

The global cysticfibrosis therapeutics market is expected to reach USD 13.9 billion by 2025, according to a new report by Grand View Research, Inc. The rising prevalence of Cystic Fibrosis (CF) globally, research & development activities undertaken by key players, and favorable initiatives undertaken by nonprofit organizations are expected to boost the market over the forecast period.

The rising prevalence of CF indicates the rising demand for treatment alternatives, thereby uplifting the market. The key players operating in this market in collaboration with nonprofit organizations focus on the development of novel therapeutics for treatment. Some of the drugs that are under clinical studies are VX-445 + tezacaftor + ivacaftor, PTI-428, QR-010, AZD5634, and POL6014.

Favorable initiatives taken by regional and national nonprofit organizations is one of the key factors propelling growth. These initiatives ensure support to CF patients. These organizations aid in research & development activities of these therapeutics and help improve the quality of life of these patients. For instance, North American Cystic Fibrosis Conference (NACFC) was formed in 1986 to provide a collaborative and educational forum to CF professionals to share advances in R&D related to CF therapeutics.

Access Full Research Report On Cystic Fibrosis (CF) Therapeutics Market  Analysis:
www.grandviewresearch.com/industry-analysis/cystic-fibrosis-cf-therapeutics-market

Further key findings from the report suggest:

·         The global CF therapeutics market size was estimated at USD 3,560.5 million in 2016 and is expected to grow at a CAGR of 16.7% from 2017 to 2025

·         The CFTR modulator segment emerged as the largest segment in 2016 and the same segment is anticipated to witness fastest growth over the next 8 years owing to the approval of CFTR modulator, Orkambi and the presence of various investigational compounds under the pipeline.

·         Oral route of administration emerged as the largest segment with revenue of USD 2,266.4 million due to the ease of administration and convenience

·         North America accounted for the largest market share owing to the presence of Caucasian descents in this region. Improved healthcare infrastructure, reimbursements, and initiatives undertaken by the nonprofit organizations is expected to propel the market over forecast period,

·         The key players include AbbVie Inc., F. Hoffmann-La Roche Ltd.; Gilead, Novartis AG, Vertex Pharmaceuticals Inc., AIT (Advanced Inhalation Therapies), Alaxia, Teva Pharmaceutical Industries Ltd, Merck & Co. Inc., Alcresta Therapeutics Inc., Allergan, and AstraZeneca

Browse More Reports Of This Category By Grand View Research At:  www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the cystic fibrosis therapeutics market on the basis of drug class, route of administration and region:

Cystic Fibrosis Therapeutics Drug Class Outlook (Revenue, USD Million, 2014 - 2025)

·         Pancreatic enzyme supplements

·         Mucolytics

·         Bronchodilators

·         CFTR modulators

Cystic Fibrosis Therapeutics Route of Administration Outlook (Revenue, USD Million, 2014 - 2025)

·         Oral drugs

·         Inhaled drugs

Cystic Fibrosis Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)

·         North America

o    U.S.

o    Canada

·         Europe

o    Germany

o    UK

·         Asia Pacific

o    China

o    Japan

·         Latin America

o    Brazil

o    Mexico

·         Middle East & Africa

o    South Africa

Access Full Press Release of this Report:
www.grandviewresearch.com/press-release/global-cystic-fibrosis-cf-therapeutics-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com/

Women’s Health Diagnostics Market Expected To Trigger A Revenue Increase To USD 76.2 Billion By 2025:Key Participant Siemens Healthcare Private Limited, Hologic, Inc.

San Francisco, 17 December 2018,  Women’s Health Diagnostics Market Size, Share & Trends Analysis Report By End Use, By Application (Cancer, Infectious Disease, Osteoporosis, Pregnancy, Prenatal), and Segment Forecasts, 2018 - 2025

The global women’s health diagnostics market size is expected to reach USD 76.2 billion by 2025, according to a new report by Grand View Research, Inc. Rising adoption of point-of-care diagnostics and growing incidence of various chronic and lifestyle diseases are among the key factors stimulating the growth of the market. Besides this, introducing various awareness programs is also anticipated to work in favor the market during the forecast period. For instance, in 2014, the European Commission launched joint action for European Guide on Quality Improvement in Comprehensive Cancer Control.

Women’s health diagnostics is witnessing high growth due to increased funding from various organizations. For instance, in May 2015, Abcodia received funding of USD 8.0 million from Cambridge Innovative Capital, Scottish Equity Partners, Albion Ventures, and UCLB to launch Risk of Ovarian Cancer Algorithm (ROCA) test in the U.K. for early detection of ovarian cancer.

On the basis of end use, the market has been bifurcated into hospital & diagnostics centers and home. Hospitals and diagnostic centers accounted for a larger share in the market due to high number of visits to hospitals and more reliable detection.

The market in Asia Pacific is likely to witness significant growth over the coming years. The growth of the market can be attributed to increasing investments in healthcare, growing focus of international device manufacturers on strengthening their distribution networks within the region, and epidemiological shift from infectious diseases to chronic diseases within regional boundaries.

Access Full Research Report On Women’s Health Diagnostics Market Analysis:
www.grandviewresearch.com/industry-analysis/womens-health-diagnostics-market

Further key findings from the report suggest:

·         Increasing investments by governments and private bodies and rising disposable income are providing a push to the market

·         Cancer accounted for the highest share in the market in 2017. The segment will register noteworthy growth during the forecast period owing to availability of early detection tests and government initiatives to tackle cancer

·         Prenatal testing is estimated to be the fastest growing segment during the same period owing to rising prevalence of prenatal diseases, increasing maternal age, surging healthcare expenditure, and development of advanced diagnostic tests

·         Geographically, North America was the leading revenue contributor to the women’s health diagnostics market in 2017. It is anticipated to maintain its dominance through 2025, thanks to widening base of diagnostic and imaging centers, mounting cases of cancer, growing awareness about fertility testing, and spiraling adoption of point-of-care testing devices

·         Some of the key players are Siemens Healthcare Private Limited; Hologic, Inc.;GE Healthcare; F. Hoffmann-La Roche Ltd.; bioMérieux SA; Koninklijke Philips N.V; Abbott; Becton, Dickinson and Company, Quest Diagnostics, Inc.; and PerkinElmer, Inc.

Browse More Reports Of This Category By Grand View Research At:   www.grandviewresearch.com/industry/clinical-diagnostics

Grand View Research has segmented the global women’s health diagnostics market based on application, end use, and region:

Women’s Health Diagnostics Application Outlook (Revenue, USD Million, 2014 - 2025)

·         Cancer

o    Breast Cancer Testing

o    Cervical Cancer Testing

o    Ovarian Cancer Testing

·         Infectious Disease Testing

·         Osteoporosis Testing

·         Pregnancy and Fertility Testing

·         Prenatal Testing

Women’s Health Diagnostics End Use Outlook (Revenue, USD Million, 2014 - 2025)

·         Hospital and Diagnostics Centers

·         Home

Women’s Health Diagnostics Regional Outlook (Revenue, USD Million, 2014 - 2025)

·         North America

o    U.S.

o    Canada

·         Europe

o    U.K.

o    Germany

·         Asia Pacific

o    Japan

o    China

·         Latin America

o    Brazil

o    Mexico

·         Middle East & Africa

o    South Africa

Access Full Press Release of this Report:
www.grandviewresearch.com/press-release/global-womens-health-diagnostics-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com/